Prediabetes is a health condition where blood sugar levels are higher than normal but not yet high enough to be classified as type 2 diabetes. It typically falls within the range of 100 to 125 mg/dL for fasting blood glucose. This condition indicates that the body is starting to have trouble regulating blood sugar, often due to insulin resistance. While prediabetes itself may not cause noticeable symptoms, it significantly increases the risk of developing type 2 diabetes, heart disease, and stroke if left unaddressed. Lifestyle changes, such as improved diet, increased physical activity, and weight management, can often reverse or delay its progression. 

The prediabetes market is experiencing steady growth, driven by several interrelated factors. One of the primary drivers is the global rise in obesity and sedentary lifestyles, which significantly increase the risk of developing prediabetes. Aging populations and urbanization are also contributing to higher prevalence rates. Additionally, improved access to healthcare and growing awareness of the long-term risks associated with untreated prediabetes—such as type 2 diabetes and cardiovascular disease—are encouraging more people to seek screening and early intervention. The introduction and increased use of effective medications, including GLP-1 receptor agonists and Metformin, are expanding treatment options. 

The global prediabetes market encounters several challenges that impede its full potential. A major hurdle is the widespread underdiagnosis of prediabetes, largely due to its silent nature and lack of clear symptoms, leading many individuals to remain unaware of their condition. This is compounded by limited public awareness and insufficient routine screening, particularly in developing and underserved regions. Access to healthcare services, diagnostic tools, and consistent monitoring remains uneven across countries, creating disparities in early detection and treatment. Additionally, most available treatments are adapted from type 2 diabetes management, with few therapies specifically approved for prediabetes, limiting targeted intervention options. Patient adherence to recommended lifestyle changes—such as diet, exercise, and weight loss—also presents a challenge, as these require long-term commitment without immediate results. 

Novo Nordisk A/S, Valbiotis, RESVERLOGIX, Caelus Health, Scimar, Boston Pharmaceuticals, APHAIA PHARMA AG, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc.

By Drug Class: Based on the Drug Class, Global Prediabetes Market is segmented as; Diguanide, Thiazolidinediones, Glucagon-like peptide-1 agonists (GLP-1), SGLT2 inhibitors, DPP-4 inhibitors, Others.

By Age Group: Based on the Age Group, Global Prediabetes Market is segmented as; {(Children (12-18 years), Adults (18-49), Elderly (50+).

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.